Mark Smith's Email Addresses & Phone Numbers

📖 Summary

Chief Financial Officer @ Sion Power Corporation Tucson, Arizona AreaExecutive Vice President & Chief Financial Officer @ Annexon Biosciences From January 2018 to May 2019 (1 year 5 months) South San FranciscoCFO @ Fluidic Energy From October 2013 to January 2016 (2 years 4 months) Scottsdale, ArizonaChief Financial Officer @ Calimmune, Inc Calimmune was successfully sold to CSL Behring, part of CSL, for $91M upfront with up to $325M in potential future milestone payments effective August 31, 2017. From February 2016 to October 2017 (1 year 9 months) Tucson, Arizona AreaCFO @ Neuromedical Systems Technology sold to Autocyte (subsequently consolidated into Tripath Imaging and transacted to Becton Dickenson) From February 1998 to August 1999 (1 year 7 months) Upper Saddle River, New JerseyGroup Contoller @ Genzyme Initially served as VP Finance for Genzyme Genetics following that business unit's acquisiton of Genetrix where I served as CFO. From March 1996 to February 1998 (2 years) Cambridge, MassachusettsCFO @ Genetrix Sold company to Genzyme in a transaction consolidating significant genetic testing companies. I transferred to Genzyme as the VP Finance for the Genzyme Genetics business unit. From June 1991 to March 1996 (4 years 10 months) Audit Manager @ Price Waterhouse Coopers Commenced career with Price Waterhouse Sydney (Group 3 Audit). After qualifying as a Chartered Accountant in 1986, I transferred to San Jose California. From January 1983 to June 1991 (8 years 6 months) CFO @ Gevo Successfully completed IPO in February 2011 raising proceeds of $123MGevo is a renewable chemicals and next generation biofuels company. Our overall strategy is to commercialize biobased alternatives to petroleum-based products using a combination of synthetic biology and chemical technology. In order to implement this strategy, we are taking a building block approach. Initially, we intend to produce and sell isobutanol from renewable feedstocks. Isobutanol is a four carbon alcohol that can be sold directly for use as a specialty chemical in the production of solvents, paints, and coatings or as a value-added fuel blendstock. Isobutanol can also be converted into butenes using straightforward dehydration chemistry deployed in the refining and petrochemicals industries today. The convertibility of isobutanol into butenes is important because butenes are primary hydrocarbon building blocks used in the production of lubricants, rubber, plastics, fibers, other polymers and hydrocarbon fuels. We believe that the products derived from isobutanol have potential applications in approximately 40% of the global petrochemicals market, representing a potential market for isobutanol of approximately 70 billion gallons per year (“BGPY”), and substantially all of the global hydrocarbon fuels market, representing a potential market for isobutanol of approximately 900 BGPY. From November 2008 to October 2013 (5 years) Englewood, ColoradoCFO @ Replidyne, Inc. Recruited to provide financial leadership to IPO that was successfully completed in June 2006.Played leadership role in strategic sale of company to Cardiovascular Systems Inc. that was completed in February 2009 From March 2006 to February 2009 (3 years) Louisville, ColoradoCFO @ Nabi Biopharmaceuticals Chief Financial Officer from April 2001 to March 2006Led several major financings including raising $112 million in a convertible debt transaction in a private transaction utilizing Form 144a (April/May 2005), raising net $91 million in a follow on secondary offering enhancing the company’s institutional investor base while providing the financial resources to complete clinical trials of primary development stage product and raising $32 million in Private Investment in a Public Entity raising funds for strategic acquisition of a product line, Played leadership role in acquisition of strategic product line Negotiated debt agreement to provide financial resources for working capital through product development cycle and strategic product acquisitionPlayed leadership role in developing corporate strategy shifting focus to biotechnology business following sale of legacy operations focused on plasma salesPlayed leadership role in disposition of a legacy business unit completing the company’s transition into a fully integrated biopharmaceutical companyLed process of initial compliance with Sarbanes Oxley Act, Section 404Responsible for finance, treasury, risk management, business development and SEC reporting maintaining responsibility as Principal Accounting OfficerFrequently meet with key investors and potential investors on behalf of the company, delivered company investor presentation at investor conferences and maintained primary relationship with investment bankers and advisers From August 1999 to March 2006 (6 years 8 months) Boca Raton, Florida